Results 121 to 130 of about 4,640 (210)

The Evolving Landscape of Systemic Therapy for Liposarcoma. [PDF]

Cancers (Basel)
Kim HK, Sarkari A, Chow WA.
europepmc   +1 more source

Selinexor enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by regulating the BAX/Bcl-2/PUMA apoptotic pathway and the XPO1/p27 cell cycle pathway. [PDF]

Front Oncol
Du S, Wang L, Chen C, Sun Y, Liu Q, Shi J, Zhang F, Wang K, Cui C.   +8 more
europepmc   +1 more source

In reply: Why selinexor remains a subpar option? [PDF]

Oncologist
Mohyuddin GR, Meirson T.
europepmc   +1 more source

Nuclear export as a therapeutic vulnerability in ZFTA-RELA ependymoma. [PDF]

Neuro Oncol
Ippagunta SM, Arabzade A, Varadharajan S, Emanus E, Bland A, Kardian A, Laboe N, Sun H, Zheng T, Hancock A, Zhai M, Caesar E, Park M, Orisme W, Johnson M, Rodgers B, Turner GH, Steinberg J, Freeman B, Roussel MF, Shelat A, Kriwacki R, Merchant TE, Deneen B, Taylor MD, Agnihotri S, Pruett-Miller S, Steele JA, Kavirayani AM, Ellison DW, Onar-Thomas A, Robinson G, Mack SC, Bertrand KC.   +33 more
europepmc   +1 more source

XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer. [PDF]

Nat Commun
Du Q, Qin T, Wang J, Jiang Y, Xu Q, Li X, Liu H, Yu J, Lu Y, Tong L, Sun T, Chen P, Jiang R, Huang D.   +13 more
europepmc   +1 more source

Comment on "how the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes". [PDF]

Oncologist
Richter J, Davis M, Chai Y.
europepmc   +1 more source

Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. [PDF]

Front Oncol
Lentz RW, Dominguez ATA, Balmaceda NB, Arcaroli JJ, Bagby SM, Binns CA, Smoots SG, Jackson MM, Macbeth M, Holmstoen T, Banerjee T, Whitty PA, Yi SS, Lieu CH, Messersmith WA, Pitts TM.   +15 more
europepmc   +1 more source

Dual epigenetic and nuclear export inhibition by chidamide and selinexor in high grade B-cell lymphomas via survivin and PI3K/AKT inhibition. [PDF]

Clin Epigenetics
Lin J, Zhuang X, Jia S, Zhou H, Qin D, Zhou J, Chen B, Zhuang M, Xu B, Zha J.   +9 more
europepmc   +1 more source

Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting. [PDF]

J Hematol Oncol
Wei R, Yang S.
europepmc   +1 more source

A new therapeutic approach to <i>KRAS</i> mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition. [PDF]

Transl Lung Cancer Res
von Itzstein MS, Gerber DE.
europepmc   +1 more source